New PET scan may predict breast cancer drug success
NCT ID NCT02226276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug T-DM1. Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal was to see if the scan's images could tell doctors which patients would benefit from T-DM1, helping avoid ineffective treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- A new test could reveal how radiation affects the liver
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out